Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Horibe, Tomohisa ^a   Kohno, Masayuki ^a   Haramoto, Mari ^a   Ohara, Koji ^a   Kawakami, Koji ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90; MEMBRANE COFACTOR PROTEIN; PEPTIDOMIMETIC AGENT; PROTEIN P60; PROTEIN TPR2A; TETRATRICOPEPTIDE REPEAT PROTEIN; UNCLASSIFIED DRUG; HOMEODOMAIN PROTEIN; HOP PROTEIN, HUMAN; HYBRID ANTP TPR PEPTIDE; HYBRID ANTP-TPR PEPTIDE; HYBRID PROTEIN; PEPTIDE FRAGMENT; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CONTROLLED STUDY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; LUNG CANCER; MOUSE; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN ENGINEERING; STOMACH CANCER; TUMOR XENOGRAFT; ANIMAL; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PHYSIOLOGY; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; HOMEODOMAIN PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PEPTIDE FRAGMENTS; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECOMBINANT FUSION PROTEINS; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78651373656     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-8     Document Type: Article

References (45)

1. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002, 295:1852-1858. 10.1126/science.1068408, 11884745.
2. Pearl LH, Prodromou C. Structural and in vivo function of Hsp90. Curr Opin Struc Biol 2000, 10:46-51.
3. Young JC, Moarefi I, Hartl FU. Hsp90: a specialized but essential protein-folding tool. J Cell Biol 2001, 154:267-273. 2150759, 11470816, 10.1083/jcb.200104079.
4. Sikorski RS, Boguski MS, Goebl M, Hieter P. A repeating amino acid motif in CDC23 defines a family of proteins and a new relationship among genes required for mitosis and RNA synthesis. Cell 1990, 60:307-317. 10.1016/0092-8674(90)90745-Z, 2404612.
5. Hirano T, Kinoshita N, Morikawa K, Yanagida M. Snap helix with knob and hole: essential repeats in S. pombe nuclear protein nuc2+. Cell 1990, 60:319-328. 10.1016/0092-8674(90)90746-2, 2297790.
6. Goebl M, Yanagida M. The TPR snap helix: a novel protein repeat motif from mitosis to transcription. Trends Biochem Sci 1991, 16:173-7. 10.1016/0968-0004(91)90070-C, 1882418.
7. Lamb JR, Tugendreich S, Hieter P. Tetratrico peptide repeat interaction: to TPR or not to TPR?. Trends Biochem Sci 1995, 20:257-259. 10.1016/S0968-0004(00)89037-4, 7667876.
8. Blatch GL, Lässle M. The tetratricopeptide repeat: a structural motif mediating protein-protein interactions. BioEssays 1999, 21:932-939. 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N, 10517866.
9. Irmer H, Höhfeld J. Characterization of functional domains of the eukaryotic co-chaperone Hip. J Biol Chem 1997, 272:2230-2235. 10.1074/jbc.272.4.2230, 8999928.
10. Prodromou C, Panaretou B, Chohan S, Siligardi G, O'Brien R, Ladbury JE, Roe SM, Piper PW, Pearl LH. The ATPase cycle of Hsp90 drives a molecular "clamp" via transient dimerization of the N-terminal domains. EMBO J 2000, 19:4383-4392. 302038, 10944121, 10.1093/emboj/19.16.4383.
11. Young JC, Obermann WM, Hartl FU. Specific binding of tetratricopeptide repeat proteins to the C-terminal 12-kDa domain of hsp90. J Biol Chem 1998, 273:18007-18010. 10.1074/jbc.273.29.18007, 9660753.
12. Ramsey AJ, Russell LC, Whitt SR, Chinkers M. Overlapping sites of tetratricopeptide repeat protein binding and chaperone activity in heat shock protein 90. J Biol Chem 2000, 275:17857-17862. 10.1074/jbc.M001625200, 10751404.
13. Chen S, Smith DF. Hop as an adaptor in the heat shock protein 70 (Hsp70) and hsp90 chaperone machinery. J Biol Chem 1998, 273:35194-35200. 10.1074/jbc.273.52.35194, 9857057.
14. Johnson BD, Schumacher RJ, Ross ED, Toft DO. Hop modulates Hsp70/Hsp90 interactions in protein folding. J Biol Chem 1998, 273:3679-3686. 10.1074/jbc.273.6.3679, 9452498.
15. Morishima Y, Kanelakis KC, Silverstein AM, Dittmar KD, Estrada L, Pratt WB. The Hsp organizer protein hop enhances the rate of but is not essential for glucocorticoid receptor folding by the multiprotein Hsp90-based chaperone system. J Biol Chem 2000, 275:6894-6900. 10.1074/jbc.275.10.6894, 10702249.
16. Bose S, Weikl T, Bugl H, Buchner J. Chaperone function of Hsp90-associated proteins. Science 1996, 274:1715-1717. 10.1126/science.274.5293.1715, 8939863.
17. Scheufler C, Brinker A, Bourenkov G, Pegoraro S, Moroder L, Bartunik H, Hartl FU, Moarefi I. Structure of TPR domain-peptide complexes: Critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine. Cell 2000, 101:199-210. 10.1016/S0092-8674(00)80830-2, 10786835.
18. Scott MD, Frydman J. Aberrant protein folding as the molecular basis of cancer. Methods Mol Biol 2003, 232:67-76.
19. Neckers L, Mimnaugh E, Schulte TW. Hsp90 as an anti-cancer target. Drug Resist Updates 1999, 2:165-172.
20. Workman P, Burrows F, Neckers L, Rosend N. Drugging the cancer chaperone Hsp90: Combinational therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci 2007, 1113:202-216. 10.1196/annals.1391.012, 17513464.
21. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003, 3:213-217. 10.1016/S1535-6108(03)00029-1, 12676580.
22. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003, 3:377-383. 10.2174/1568009033481831, 14529389.
23. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003, 15:419-424. 10.1097/00001622-200311000-00003, 14624223.
24. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002, 21:1159-1166. 10.1038/sj.onc.1205184, 11850835.
25. Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y, Gabrilovich DI, Colombo G, Altieri DC. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005, 7:457-468. 10.1016/j.ccr.2005.03.035, 15894266.
26. Gyurkocza B, Plescia J, Raskett CM, Garlick DS, Lowry PA, Carter BZ, Andreeff M, Meli M, Colombo G, Altieri DC. Antileukemic activity of shepherdin and molecular diversity of Hsp90 inhibitors. J Natl Cancer Inst 2006, 98:1068-1077. 10.1093/jnci/djj300, 16882944.
27. Salvesen GS, Duckett CS. Apoptosis: IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002, 3:401-410. 10.1038/nrm830, 12042762.
28. Altieri DC. Validating surviving as a cancer therapeutic target. Nat Rev Cancer 2003, 3:46-54. 10.1038/nrc968, 12509766.
29. Kabouridis PS. Biological application of protein transduction technology. Trends Biotechnol 2003, 21:498-503. 2597147, 14573363, 10.1016/j.tibtech.2003.09.008.
30. Brinker A, Scheufler C, Von Der Mulbe F, Fleckenstein B, Herrmann C, Jung G, Moarefi I, Hartl FU. Ligand discrimination by TPR domains. Relevance and selectivity of EEVD-recognition in HSp70 - Hop - Hsp90 complexes. J Biol Chem 2002, 277:19265-19275. 10.1074/jbc.M109002200, 11877417.
31. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 27:680-685.
32. Horibe T, Nagai H, Sakakibara K, Hagiwara Y, Kikuchi M. Ribostamycin inhibits the chaperone activity of protein disulfide isomerase. Biochem Biophys Res Commun 2001, 289:967-972. 10.1006/bbrc.2001.6105, 11741285.
33. Zhao Q, Wang J, Levichkin IV, Stasinopoulos S, Ryan MT, Hoogenraad NJ. A mitochondrial specific stress response in mammalian cells. EMBO J 2002, 21:4411-4419. 126185, 12198143, 10.1093/emboj/cdf445.
34. Shin M, Nakamuta H, Oda-Ueda N, Larsson LI, Fujiwara K. Immunocytochemical demonstration of polyamines in nucleoli and nuclei. Histochem Cell Biol 2008, 129:659-665. 10.1007/s00418-008-0400-4, 18301910.
35. Young JC, Hoogenraad NJ, Hartl FU. Molecular chaperones Hsp90 and Hsp70 deliver preproteins to the mitochondrial import receptor Tom70. Cell 2003, 112:41-50. 10.1016/S0092-8674(02)01250-3, 12526792.
36. Zhang H, Chung D, Yang YC, Neely L, Tsurumoto S, Fan J, Zhang L, Biamonte M, Brekken J, Lundgren K, Burrows F. Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther 2006, 5:1256-1264. 10.1158/1535-7163.MCT-05-0537, 16731758.
37. Song D, Chaerkady R, Tan AC, García-García E, Nalli A, Suárez-Gauthier A, López-Ríos F, Zhang XF, Solomon A, Tong J, Read M, Fritz C, et al. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol Cancer Ther 2008, 7:3275-3284. 10.1158/1535-7163.MCT-08-0508, 18852131.
38. Kawakami K, Kawakami M, Husain SR, Puri RK. Targeting interleukin-4 receptors for effective pancreatic cancer therapy. Cancer Res 2002, 62:3575-3580.
39. Kawakami K, Kawakami M, Puri RK. Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease. Mol Cancer Ther 2004, 3:137-147.
40. Kawakami K, Terabe M, Kioi M, Berzofsky JA, Puri RK. Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suprresion of IL13R alpha2-expressing contralateral tumors. Clin Cancer Res 2006, 12:4678-4686. 10.1158/1078-0432.CCR-06-0192, 16899618.
41. Kreitman RJ. Immunotoxins for targeted cancer therapy. AAPS J 2006, 8:E532-551. 2761061, 17025272, 10.1208/aapsj080363.
42. Li Z, Yu T, Zhao P, Ma J. Immunotoxins and cancer therapy. Cell Mol Immunol 2005, 2:106-112.
43. Posey JA, Khazaeli MB, Bookman MA, Nowrouzi A, Grizzle WE, Thornton J, Carey DE, Lorenz JM, Sing AP, Siegall CB, LoBuglio AF, Saleh MN. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002, 8:3092-3099.
44. Cortajarena AL, Yi F, Regan L. Designed TPR modules as novel anticancer agents. ACS Chemical Biology 2008, 3:161-166. 10.1021/cb700260z, 18355005.
45. Guillemard V, Saragovi HU. Novel approaches for targeted cancer therapy. Curr Cancer Drug Targets 2004, 4:313-326. 10.2174/1568009043332989, 15180497.